ada guidelines glp 1 Management of Latent Autoimmune Diabetes in Adults Key 2026 ADA Guideline Updates

These mechanistic findings provide a biological foundation for the CV benefits observed in clinical trials and support further exploration of novel incretinbased therapies across cardiometabolic disorders

Investigations into GLP-1 receptor agonists have shown that these medications do not markedly elevate pancreatic or thyroid cancer risks, providing some assurance for their extended application

They are prescribed based on medical necessity and individualized assessment

In an AD mouse model, liraglutide reduces the activation of the NLR family pyrin domain containing 3 (NLRP3) inflammasome in the microglia, leading to the decreased production of proinflammatory cytokines and A plaques [52]